US2002006926A1PendingUtilityA1

Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease

32
Priority: Apr 19, 2000Filed: Apr 17, 2001Published: Jan 17, 2002
Est. expiryApr 19, 2020(expired)· nominal 20-yr term from priority
Inventors:H.H. Roylance
A61P 43/00A61K 31/519A61P 25/16A61K 31/437A61K 31/00A61K 31/4985
32
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates generally to novel therapeutic methods for treating Parkinson's Disease by administering cyclic GMP-specific phosphodiesterase inhibitor compounds.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method of treating Parkinson's disease comprising administering a therapeutically effective mount of a compound that inhibits cGMP-specific phosphodiesterase (PDE5).

Join the waitlist — get patent alerts

Track US2002006926A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.